

SUBJECT INDEX TO VOLUME 3

- Abciximab 174
 reopro/primary PTCA organization of 174
 to lower late angioplasty complications (CADI-LLAC) trial 174
 Action potential duration 105
 prolongation of 105
 Activated protein C (APC) 119
 Acute myocardial infarction (AMI) 173
 abciximab/carbostent evaluation (ACE) trial for 176
 abciximab in 173
 before direct angioplasty/stenting in 174
 eptifibatide in 177
 glycoprotein IIb/IIIa inhibitors in 173
 intracoronary stenting/antithrombotic regimen (ISAR)-2 trial of 174
 metanalysis of abciximab-PCI-AMI trials for 177
 percutaneous mechanical intervention for 173
 tirofiban in 177
 α_{1a} -Adrenergic receptors 336
 stimulation of 336
 Aldosterone 261
 classical epithelial effects of 261
 Aminopeptidases 29
 Anemia 297
 clinical/prognostic significance of 297
 in CHF/survival 298
 interventional studies in heart failure patients 302
 severity of CHF and 298
 Angiotensin II receptor blocking agents 61
 basic studies of 62
 human studies of 63
 in heart 62
 in left ventricular hypertrophy 61
 large-scale interventions of 64
 mechanism of action of 62
 pharmacokinetics of 61
 pharmacology of 61
 special groups of 62
 structure of 61
 transgenic animal models in 63
 Angiotensin II type-1 receptor 305
 in vascular dysfunction 305
 role of protein kinases 305
 signal transduction research of 305
 structural requirement for 305
 Angiotensin II type I receptor blocker 133
 effects on endothelial function 136
 effects on endothelial function in CAD 139
 effects on endothelial function in diabetes mellitus 138
 effects on endothelial function in healthy subjects 139
 effects on endothelial function in hypercholesterolemia 138
 in humans 133
 in hypertensive patients 136
 increase in NO production by 139
 long-term large clinical trials on 133
 Angiotensin-(1-7) 383
 effect on blood 383
 effect on blood vessels 383,386
 effect on heart 383
 effect on hematopoietic tissues 383
 metabolism of 383
 therapeutic applications of 386
 Anticonvulsants 181
 antioxidant therapy and 181
 Anti-proliferative drug 221
 Antithrombotics 1
 antistatin as 7
 challenges/opportunities for development of 8
 discovery of 1
 from hematophagous invertebrates 1
 hirudin as 6
 leech anti-platelet protein as 7
 mechanisms of action of 1
 molecular targets of 1
 nematode anticoagulant peptides as 6
 parasite derived 1
 pre-clinical development 1
 role in biology of bloodfeeding invertebrates 5
 tick anticoagulant peptide (TAP) as 7
 Arrhythmia 336
 anthracene-9-carboxylic acid for 336
 Aspirin 203
 adverse effects of 206
 chemical structure of 205
 in acute myocardial infarction 205
 in cardiology 203
 in cerebrovascular disease 206
 in non-ST elevation myocardial infarction 205
 in post-myocardial infarction 205
 in primary prevention of cardiovascular risk 206
 in stable angina 206
 in unstable angina 205
 mechanisms of action of 204
 pharmacodynamics of 205
 pharmacokinetics of 205
 resistance of 207
 Aspirin/clopidogrel 211
 adverse effects of 214
 after intracoronary irradiation (brachytherapy) 214
 after noncardioembolic ischemic stroke 214
 in acute syndromes 211
 in cardioembolic ischemic stroke 214
 indications of 215
 AT₁ receptor 306
 activation of protein kinase by 306
 G protein coupling of 316
 internalization/desensitization of 316
 mediates growth/migration of VSMCS 306
 regulation of downstream signaling of 316
 studies using AT₁ mutants for 315

ATP-sensitive K ⁺ channels (I _{KATP})	337	vascular effects of	262
Atrial natriuretic peptide (ANP)	11	vascular synthesis of	263
as protective agent	18	Cardiovascular antithrombotic therapy	357
as vascular anti-growth factor	12	by antiplatelet agents	358
by induction of cytoprotective proteins	14	by aspirin	359
cGMP target molecules and	16	by fibrinolytic drugs	361
effect on leukocyte attraction/adhesion	14	by GP IIb/IIIa receptor inhibitors	360
endothelial permeability of	12	by low molecular weight heparin	360
vasoprotective actions of	11	by oral anticoagulants	360
Bare metal stents	212	by thienopyridine derivatives	359
Brain natriuretic peptide (BNP)	87	by unfractionated heparin	360
as prognostic parameter in heart disease	93	pharmacogenetics in	357
biological actions of	92	Cardiovascular calcification	167
in assessing left ventricular (LV) function after		clinical impact of	167
myocardial infarction	92	Cardiovascular diseases	157
in diagnosis of heart failure	92	genetic polymorphisms in	157
in monitoring treatment of heart failure	92	pharmacotherapies for	163
measurement of	92	prevention of	157,163
molecular biology in	92	role of prostacyclin synthase gene	157
Calcitonin receptor-like receptor (CRLR)	232	Cardiovascular prognosis	55
discovery of	232	influence of chronic kidney disease	
Calmodulin	283	development on	55
role in GPVI	285	renin-angiotensin system inhibition on	55
role in L-selectin shedding	284	Cellular repolarization	108
role in PECAM-1	286	transmural heterogeneity of	108
role in platelet receptor function	283	Central nervous system	38
role in thrombosis	286	role of kinins	38
role in GPIb-IX-V	285	Chloride channels	333
Cardiac adrenomedullin	231	in hypotonic swelling	333
acute administration in heart failure	239	in RVD of cardiomyocytes	333
cardiac actions of	232	modulators of	333
circulating levels in heart failure	235	volume regulated	335
effect on cardiac contractility	232	Chronic heart failure	149,297
effect on local action	233	anemia in	297
in cardiac hypertrophy	236	antiplatelets anticoagulation in	151
in metabolic sites of plasma	234	frequency of anemia in patients with	297
molecular forms of	234	incidence/significance of thrombo-embolism in ..	150
origin of	234	low molecular weight heparin anti-coagulation in	152
in plasma	234	mechanism of thromboembolism in	150
receptor of	232	pathophysiologic models of anemia in	300
role in cardiac hypertrophy	231	pharmacological intervention of	149
role in heart failure	231,238	Chronic kidney disease	57
role in LVH	238	cardiovascular risk factors of	57
structure of	231	prevention of	57
tissue distribution of	231	treatment of	57
Cardiac surgery	323	Chymase	25
arterial line leukofiltration in	324	CL ₂ PKA	336
leukocyte filtration of blood cardioplegia in	325	non-selective blockers of	336
strategic leukofiltration in	323	selective blockers of	336
Cardiovascular aldosterone	261	Clopidogrel	203
cardiac effects of	263	chemical structure of	207
cardiac synthesis of	264	clinical results of	209
cardiovascular effects of	262	drug interactions of	208
in hypertension	261	in acute coronary syndromes	210
role of	261	in cardioembolic ischemic stroke	209
		in cardiology	203
		in non-cardioembolic ischemic stroke	209

- in patients after coronary artery bypass grafting .. 210
 in peripheral arterial occlusive disease 209
 mechanism of action of 207
 pharmacokinetics of 207
 resistance of 211
 safety profile of 210
 Coronary atherosclerosis 379
 relationship between preheparin LPL mass..... 379
 Coronary heart disease 289
 homocysteine-lowering treatment in 289
 role of vitamins 291
 Coronary stent restenosis 221
 ABT-578 in 226
 anti-proliferative drugs in 221
 biolimus A9 in 226
 drug-eluting stents in 224
 everolimus in 224
 other drugs for 226
 paclitaxel in 222
 prevention of 221
 sirolimus in 221
 tacrolimus (FK506) in 226

 DCPIB 336
 Decompensated heart failure 243
 Delayed rectifier potassium channels- I_{Ks} 337
 for chromanol 293B..... 337
 for L-786,673 337
 Dideoxyforskolin (DDF) 336
 4,4'-Diisothiocyanostilbene-2,2'-disulfonate (DIDS) 335
 selective blockers of 335
 Disintegrin-like domain 249
 clinical roles of 256
 comparison of 253
 in Adam family of proteins 253
 in snake venom metalloproteinase 249
 interaction with integrins 249
 structure-activity relationships of 249,253
 Dopamine metabolism..... 69
 interaction with arginine vasopressin..... 74
 interaction with atrial natriuretic peptide (ANP) 73
 interaction with endothelin B (ETB) receptor..... 74
 interaction with nitric oxide (NO)..... 73
 interaction with prostaglandins 74
 Dopamine receptor 69
 activation on resistance vessels 71
 impaired function in hypertension 71
 in hypertension 69
 interaction with other systems 73
 interaction with reactive oxygen species (ROS)..... 73
 interaction with rennin-angiotensin-
 aldosterone system 73
 interaction with sympathetic nervous system..... 73
 natriuretic/diuretic effects of 70
 physiologic role of 70
 role of protein kinase A/C..... 70

 Drug-eluting stents (DES) 212,221
 cost of 228
 limitations of 227
 local adverse effects of 228
 risk of stent thrombosis after implantation of 227
 systemic secondary effects of 227
 Drug-induced prolongation 105
 molecular predictors of 105
 of QT interval 105
 Drug-induced TDP 115
 treatment of 115
 Dyslipidemia 187
 critical values of 188
 framingham study of 187
 in obesity 189
 life time risk of 187
 lipid profiles in 188
 multivariable risk of 189
 preventive implications of 192
 preventive treatment guidelines for 191
 risk factor clustering of 189
 risk stratification of 187

 Eclampsia 184
 End stage renal disease (ESRD) 165
 diagnosis of 165
 prevention of 165
 vascular calcification in 165
 Endogenous estrogens 46
 in women 46
 Endothelial function 133
 bradykinin-NO pathway of 139
 catalase in 143
 EDHF in 145
 endothelin-1 in 144
 endothelium-derived vasodilators in 145
 eNOS in 141
 GPx in 143
 in atherosclerosis 135
 in humans 133
 mechanical pressure in 144
 norepinephrine in 144
 of assessment humans 134
 prostacyclin in 145
 putative mechanisms by ARB improves 139
 rhoA/rho-kinase in 144
 role of antioxidant system 143
 role of vasoconstrictors 144
 SOD in 143
 Endothelial protein C receptor (EPCR) 119
 in inflammation 127
 Endthelial dysfunction 311
 induced by angII *via* AT₁ 311
 Estradiol metabolism 45
 Ethnopathogenesis 165
 calcimimetic agents for 170
 calcium-based phosphate binders for 169

- diagnostic tools for 167
 lanthanum carbonate for 170
 sevelamer for 169
 therapeutic approaches for 169
 vitamin D analogues for 170
- Failing heart 243
 contractile performance of 243
 novel mechanism of drug-induced
 improvement in 243
- Fibrinolysis 341
 as interfacial process 345
 at fluid-solid interface in thrombi 341
 in fibrin degradation 348
 locus of 341
 methodology for evaluation of interfacial
 model of 349
 modeling of kinetics of 347
 role of fibrin mesh 341
- Fibrinolytic system 344
 inhibitors of 344
- Glycoprotein (GP) IIb/IIIa (α IIb β 3) 99
 development of 99
 inhibit platelet fibrinogen binding by 99
 peptides from 99
- Glycoprotein IIb (α IIb) 100
 peptides containing rad (argalaasp) sequence
 derived form 100
- Glycoprotein IIIa (β 3) 100
 peptides derived from 100
- GSMTX-4 338
 from *Grammostola spatulata* spider 338
- HIV disease 365
 clinical relevance of 360
 for antiretroviral treatments 369
 in immunoglobulins 368
 in splenectomy 368
 in transfusion 369
 interferon alpha /interleukin-6 in 371
 interleukin-3 in 372
 interleukin-11 in 372
 management of 365
 mechanisms of thrombocytopenia in 365
 megestrol acetate in 369
 physiopathology of 365
 role of thrombopoietin 371
 therapeutic targets under investigation 370
 thrombocytopenia in 365
 treatment of 372
 use of glucocorticoids/danazol in 367
- Homocysteine 289
 in END-stage renal disease 293
 prognostic value of 291
- Homocysteine-induced cell damage 272
 mechanisms of 272
- Hormone replacement therapy 45
 complex effects on estrogen metabolism 49
 smoking-related impairment of osteoporosis
 prevention by 46
- 3-Hydroxy-3-methylglutaryl-coenzyme A reductase
 inhibitors 195
 anti-inflammatory effects of 196
 candidate mechanisms of 195
 effects on coagulation systems 197
 effects on smooth muscle cell proliferation/
 migration 197
 effects on transporters 199
 for anti-lipid deposition in blood vessels 195
 hydrophilicity of 198
 in intestine 198
 in liver 198
 inhibition of cytokine/chemokine
 production by 196
 lipophilic statin-specific pleiotropic
 effects of 199
 lipophilicity of 198
 mechanism of action of 199
 nonspecific pleiotropic effects of 199
 pleiotropic effects of 195,196
 role of transporter mechanisms on
 antiatherogenic action of 198
 transport mechanisms of 198
- Insulin resistance 349
 relationship between preheparin LPL mass 379
- Invertebrate parasites 5
 evolution of blood feeding by 5
- Ion channels 333
 activated by hypotonic swelling 333
 in cardiomyocytes 333
 in pharmacological treatment of life-
 threatening arrhythmias 333
 modulators of 333
- K⁺ channels 337
 in cardiac cell hypotonic swelling/modulators 337
- Kinin receptors 35
- Kininase 34
- Kininogen-kinin system 33
 components of 33
 direct cardioprotector effect of 39
 drugs acting on 36
 effect of angiotensin converting enzyme inhibitors 37
 effect of kallikrein inhibitors 37
 effect of kinin receptor antagonists 37
 hageman factor-dependent pathway of 33
 in plasma 33
 in tissue 33
 modulation of cardiovascular system by 38
 regulation of arterial blood pressure by 38
 role in cardiovascular system 33
 vascular effects of 38

- Left ventricular dysfunction 152
 and survival 152
 warfarin anticoagulation in 152
- Leukocyte 323
 role of 323
- Leukocyte filtration 323
 blood cardioplegia filters of 325
 clinical evaluation of 326
 dilemmas on 325
 functions of 325
 low volume blood cardioplegia filters of 325
 mechanism of action of 325
 salvaged blood 325
 structure of 325
 technique/devices for 325
- Levosimendan 243
 anti-apoptotic effects in advanced heart failure 245
 anti-apoptotic effects of 243
 anti-inflammatory effect of 243,245
 biologic/pharmacologic effects of 243
 clinical benefits in congestive/decompensated
 heart failure 244
 in decompensated heart failure 243
- Lipid deposition 195
 in aorta 195
- Liposomes 387
 as sustained/controlled release systems for
 Ang-(1-7) 387
 as tool for site-specific chronic infusion of
 Ang-(1-7) 388
in vivo fate of 387
- Liver methionine metabolism 267
 development of hyper-homocysteinemia by
 impaired 269
 effect in inflammation 267
 effect on development of vascular disease 267
 influence of impaired 267
 in inflammation 274
 in mammals 267
 pharmacological interventions in liver disease 276
- Mature/glycine-extended AM 234
- Metabolic syndrome 377
 clinical determination of 377
 severity of 377
- Natriuretic peptide 11,87
 and ontogeny 90
 assays for 91
 benefits in other pathologies 94
 biological functions of 88
 in cirrhosis with ascites 92
 in congestive heart failure (CHF) 94
 in essential hypertension 93
 in heart 91
 in hypertension 91
 in renal failure 91,93
- in skeletal development 92
 in stroke 91
 in thyroid function 92
 measurement of 90
 pre-analytical factors of 90
 receptors of 88
 relevance pathophysiological states to 91
 therapeutic aspects of 93
- Natriuretic peptide family (NPF) 87
 and ontogeny 90
 benefits in other pathologies 94
 biochemistry of 87
 in cirrhosis with ascites 92
 in congestive heart failure (CHF) 94
 in essential hypertension 93
 in heart 91
 in hypertension 91
 in renal failure 91,93
 in skeletal development 92
 in stroke 91
 in thyroid function 92
 measurement of 90
 members of 87
 molecular biology of 87
 pre-analytical factors of 90
 relevance pathophysiological states to 91
 therapeutic aspects of 93
- Naturally occurring anticoagulants 6
 in vertebrate models of thrombosis 6
- Neutral endopeptidase 24.11(Neprilysin) 28
- Nitric oxide 133
 effect of NADH/NADPH oxidase 141
 inactivation of 141
 in oxidative stress 133
- Nitric oxide (NO)-NOS system 196
 normalization of 196
- Non-selective cation (NSC) channels 337
 and gadolinium (Gd³⁺) 338
 in cardiac cell hypotonic swelling/modulators 337
- Oxidative stress 141
 restoration of 141
- P IIb/IIIa inhibitors 173
 abciximab as 173
- Percutaneous coronary interventions (PCI) 212
- Plasmin 343
- Plasminogen 343
- Preeclampsia 181
 and oxidative stress 183
 antioxidants in 183
 antiplatelet agents in 181
 antithrombotic agents in 182
 pharmacologic approaches to 181
 prevention of 181
 secondary prevention of 181

- tertiary prevention of 184
 unbalanced platelet activation in 181
 use of magnesium sulfate 184
 Preheparin lipoprotein lipase mass 377
 in serum lipid metabolism 377
 marker of metabolic syndrome 377
 significance of 377
 Prekallikrein 33
 Pro-BNP 92
 molecular biology in 92
 Prostacyclin (PGI₂) 157
 physiological roles of 157
 Prostacyclin synthase (PGIS) 157
 and polymorphisms to cardiovascular diseases ... 158
 gene of 158
 peptide of 158
 relationship of genetic mutations 158
 Protein C system 119
 activation of 120
 anti-apoptotic role of 127
 anticoagulant function of activated 120
 anticoagulant role of 120
 anti-inflammatory mechanisms of 123,125
 assays of 121
 in coagulation 123
 in fibrinolysis 121
 in inflammation 123,124
 in thrombosis 121
 multifunctional 119
 neuroprotective role of 127
 regulation of 121
 Protein kinases 309
 in contractility of VSMCs induced by angII 311
 in VSMC migration through AT₁ 309
 Protein S/C4b-binding protein 126
 in inflammation 126
 QT interval 105
 by antiarrhythmic drugs 111
 by antihistaminics 113
 by antimicrobial/antimalarial drugs 113
 by bradyarrhythmias 114
 by drug interactions 113
 by ketanserin 113
 by miscellaneous drugs 113
 by psychiatric drugs 113
 by sympathetic activity 114
 by vasodilators 113
 gender effect of 114
 genotype associations of 109
 in heart failure 115
 in hypertrophy 115
 ionic current in 109
 mechanisms involved in prolongation of 105
 prolongation drugs by 111
 rapidly activating delayed rectifier current (I_{Kr}) in 109
 Receptor activity modifying protein (RAMP) system ... 232
 Renal function 55
 cardiovascular risk of 56
 derrangement of 56
 during long-term follow-up in hypertensive patients 55
 impairment in long-term treated hypertensive patients 55
 Rennin 23
 Rennin-angiotensin system 23
 inhibition of 29
 of targeting 23
 Rennin inhibitors 25
 in angiogenesis 27
 in heart 26
 in renal disease 27
 in vascular 27
 Repolarization 115
 clinical assessment of drug effects on 115
 detection of drug-induced effects on 115
 pre-clinical assessment of drug effects on 115
 Serine/threonine kinases 309
 in angII-induced VSMC growth responses 309
 Smoking 45
 Snake venom disintegrin-like proteins 253
 Snake venom metalloproteinases (SVMPS) 250
 classification of 250
 comparison of 253
 structure of 250
 disintegrin-like domain with disintegrins 251
 Tamoxifen 335
 Tatins 196
 anti-inflammatory effects of 196
 effect on transporters 199
 effects on coagulation systems 197
 effects on smooth muscle cell proliferation/
 migration 197
 hydrophilicity of 198
 in intestine 198
 in liver 198
 inhibition of cytokine/chemokine
 production by 196
 lipophilicity of 198
 lipophilic statin-specific pleiotropic effects of 199
 mechanism of action of 199
 nonspecific pleiotropic effects of 199
 pleiotropic effects of 196
 role of transporter mechanisms on
 antiatherogenic action of 198
 transport mechanisms of 198
 Thrombin-thrombomodulin (TM) complex 119
 Thrombocytopenia 365
 clinical relevance of 360
 for antiretroviral treatments 369

immunoglobulins in.....	368	genotype associations of	109
interferon alpha /interleukin-6 in	371	in heart failure	115
interleukin-3 in.....	372	in hypertrophy	115
interleukin-11 in	372	ionic current in	109
management of	365	mechanisms involved in prolongation of	105
mechanisms of action of.....	367	provocation of	105
megestrol acetate in	369	rapidly activating delayed rectifier current (I_{Kr}) in	109
physiopathology of.....	365	Tyrosine kinases	306
role of thrombopoietin	371	in growth promoting signal transduction	306
splenectomy in	368	Urodilatin	93
therapeutic targets under investigation.....	370	singularity of	93
therapies for	367	Vascular 11β -HSD2	264
transfusion in	369	Vascular calcification	165
use of glucocorticoids/danazol in.....	367	calcimimetic agents for	170
Thromboemboli	151	calcium-based phosphate binders for	169
anticoagulant therapy in prevention of	151	diagnosis of	165
Thrombophilic disorders	182	ethiopathogenesis of	165
Thromboulin	126	lanthanum carbonate for	170
in inflammation	126	pathology of	165
Thrombus	350	prevention of	165
as compartment of heterogeneous composition		sevelamer for	169
targeted by fibrinolysis.....	350	therapeutic approaches for	169
Torsade de pointes (TdP)	105	vitamin D analogues for	170
by antiarrhythmic drugs	111	Vascular insulin resistance	313
by antihistaminics	113	AT ₁ mediated	313
by antimicrobial/antimalarial drugs	113	Vasopeptidase inhibitors	94
by bradyarrhythmias	114	Verapamil	335
by drugs	111	Visceral adiposity.....	379
by drug interactions	113	relationship between preheparin LPL mass.....	379
by electrolyte/metabolic disorders	114	Women smokers.....	48
by ketanserin	113	hormonal effects on cardiovascular system	46
by miscellaneous drugs	113		
by psychiatric drugs	113		
by sympathetic activity	114		
by vasodilators	113		
drug-induced	114		
electrophysiological basis of	110		
gender effect of	114		